Maravai LifeSciences Holdings, Inc. (MRVI)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 12.06% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- What Is Maravai’s (MRVI) Comeback Really Worth to Investors?
- TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
- Maravai LifeSciences Holdings (MRVI) Rebounded Sharply, Is The Upside Already Priced In?
- Maravai (MRVI) Q2 2026 Earnings Call Transcript
- Maravai LifeSciences Q2 Earnings Call Highlights
- How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance
- Maravai (MRVI) Q1 2026 Earnings Transcript
- Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Maravai LifeSciences Holdings, Inc..
Full MRVI Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.